AC
GILD icon

Amici Capital’s Gilead Sciences GILD Stock Holding History

Amici Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-50,000
Closed -$3.96M – 69
2016
Q3 		$3.96M Buy
+50,000
New +$4.06M 1.03% 32
2015
Q1 		– Sell
-4,000
Closed -$377K – 131
2014
Q4 		$377K Buy
+4,000
New +$414K 0.02% 101

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amici Capital's GILD Position: Q4 2016 in Review

Amici Capital sold out of Gilead Sciences (GILD) in Q4 2016, closing a stake of 50,000 shares — an estimated $3.96M sold.

Amici Capital first reported a position in GILD in Q4 2014 and held it in 2 quarters. The position peaked at $3.96M in Q3 2016. 1,573 funds tracked by Wall St. Rank hold GILD as of Q4 2016.

  • Amici Capital reported no remaining Gilead Sciences position as of Q4 2016 after selling out during the quarter.
  • Amici Capital sold 50,000 Gilead Sciences shares in Q4 2016, an estimated $3.96M.
  • Amici Capital first reported a position in Gilead Sciences in Q4 2014 and held it in 2 quarters.
  • Amici Capital's Gilead Sciences position peaked at $3.96M in Q3 2016.
  • 1,573 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2016.

Based on Amici Capital's 13F filing for Q4 2016, filed 14 Feb 2017.